Octreotide reduces hepatic, renal and breast cystic volume in autosomal-dominant polycystic kidney disease

被引：0
作者：
Ramón Peces
Emilio Cuesta-López
Carlos Peces
Virginia Pérez-Dueñas
Cristina Vega-Cabrera
Rafael Selgas
机构：
[1] Hospital Universitario La Paz,Servicio de Nefrología
[2] Hospital Universitario La Paz,Servicio de Radiología
[3] Area de Tecnología de la Información,undefined
[4] SESCAM,undefined
来源：
International Urology and Nephrology | 2011年 / 43卷
关键词：
ADPKD; cAMP; Fibrocystic disease of breast; Octreotide; Renal function; Volume change;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
A 43-year-old woman with autosomal-dominant polycystic kidney disease (ADPKD) received octreotide for 12 months, and this was associated with a 6.3% reduction in liver volume, an 8% reduction in total kidney volume and stabilization of renal function. There was also a reduction of cyst size in fibrocystic disease of breast. These data suggest that the cyst fluid accumulation in different organs from patients with ADPKD is a dynamic process which can be reversed by octreotide. This is the first report of a case of simultaneous reduction in hepatic, renal and breast cystic volume with preservation of renal function in a patient with ADPKD receiving octreotide.
引用
收藏
页码：565 / 569
页数：4
相关论文
共 66 条
[1]  
Maleki D(2009)Cystic changes of breast in a family with autosomal dominant polycystic kidney disease Iran J Kidney Dis 3 246-248
[2]  
Ghafari A(2004)Outcomes of sonography-based management of breast cysts Am J Surg 188 443-447
[3]  
Vargas HI(2007)Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3′,5′-cyclic monophosphate Gastroenterology 132 1104-1116
[4]  
Vargas MP(2005)Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease Kidney Int 68 206-216
[5]  
Gonzalez KD(2009)Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial Gastroenterology 137 1661-1668
[6]  
Eldrageely K(2006)Volume progression in polycystic kidney disease N Engl J Med 354 2122-2130
[7]  
Khalkhali I(2009)Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months Kidney Int 75 235-241
[8]  
Masyuk TV(2008)Somatostatin analogues reduce liver volume in polycystic liver disease Gut 57 1338-1339
[9]  
Masyuk AI(1996)Octreotide N Engl J Med 334 246-254
[10]  
Torres VE(2009)Rapamycin reduces kidney volume and delays the loss of renal function in a patient with autosomal-dominant polycystic kidney disease Nephrol Dial Transpl PLUS 2 133-135
1234567